These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
927 related articles for article (PubMed ID: 17689367)
1. Minimal uptake of sterile drug preparation equipment in a predominantly cocaine injecting population: implications for HIV and hepatitis C prevention. Morissette C; Cox J; De P; Tremblay C; Roy E; Allard R; Stephenson R; Graves L Int J Drug Policy; 2007 May; 18(3):204-12. PubMed ID: 17689367 [TBL] [Abstract][Full Text] [Related]
2. Changes in injecting practices associated with the use of a medically supervised safer injection facility. Stoltz JA; Wood E; Small W; Li K; Tyndall M; Montaner J; Kerr T J Public Health (Oxf); 2007 Mar; 29(1):35-9. PubMed ID: 17229788 [TBL] [Abstract][Full Text] [Related]
3. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055 [TBL] [Abstract][Full Text] [Related]
4. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia. Vicknasingam B; Narayanan S; Navaratnam V Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801 [TBL] [Abstract][Full Text] [Related]
5. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003. Emmanuelli J; Desenclos JC Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629 [TBL] [Abstract][Full Text] [Related]
6. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. Koester S; Glanz J; Barón A AIDS Behav; 2005 Mar; 9(1):27-39. PubMed ID: 15812611 [TBL] [Abstract][Full Text] [Related]
7. Syringe exchanges: a public health response to problem drug use. Cox GM; Lawless MC; Cassin SP; Geoghegan TW Ir Med J; 2000; 93(5):143-6. PubMed ID: 11072923 [TBL] [Abstract][Full Text] [Related]
8. "I inject less as I have easier access to pipes": injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed. Leonard L; DeRubeis E; Pelude L; Medd E; Birkett N; Seto J Int J Drug Policy; 2008 Jun; 19(3):255-64. PubMed ID: 18502378 [TBL] [Abstract][Full Text] [Related]
9. Use of supervised injection facilities and injection risk behaviours among young drug injectors. Bravo MJ; Royuela L; De la Fuente L; Brugal MT; Barrio G; Domingo-Salvany A; Addiction; 2009 Apr; 104(4):614-9. PubMed ID: 19215603 [TBL] [Abstract][Full Text] [Related]
10. [Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia]. Huntington S; Folch C; González V; Meroño M; Ncube F; Casabona J Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):236-8. PubMed ID: 19695744 [TBL] [Abstract][Full Text] [Related]
11. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463 [TBL] [Abstract][Full Text] [Related]
12. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M; Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278 [TBL] [Abstract][Full Text] [Related]
13. Irish injecting drug users and hepatitis C: the importance of the social context of injecting. Smyth BP; Barry J; Keenan E Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970 [TBL] [Abstract][Full Text] [Related]
14. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731 [TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352 [TBL] [Abstract][Full Text] [Related]
16. Client satisfaction and risk behaviours of the users of syringe dispensing machines: a pilot study. Islam M; Stern T; Conigrave KM; Wodak A Drug Alcohol Rev; 2008 Jan; 27(1):13-9. PubMed ID: 18034377 [TBL] [Abstract][Full Text] [Related]
17. New syringe acquisition and multi-person use of syringes among illegal drug users. Richard AJ; Mosier V; Atkinson JS J Public Health Policy; 2002; 23(3):324-43. PubMed ID: 12325289 [TBL] [Abstract][Full Text] [Related]
18. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany. Stark K; Herrmann U; Ehrhardt S; Bienzle U Epidemiol Infect; 2006 Aug; 134(4):814-9. PubMed ID: 16371183 [TBL] [Abstract][Full Text] [Related]
19. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users. Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668 [TBL] [Abstract][Full Text] [Related]
20. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty. Rhodes T; Davis M; Judd A Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]